Back to Peptides
Tesofensine
Metabolic & Weight LossTesofensine is a triple monoamine reuptake inhibitor (SNDRI) studied for appetite suppression and weight loss. Originally developed for neurodegenerative diseases, it showed significant weight reduction in clinical trials for obesity.
Administration
Oral
mg capsule/tablet
Daily Range
0.25–1 mg Oral
once daily
Standard Dose
0.5 mg
Cycle
4–8 weeks
then reassess
weight lossobesity managementserotonin-noradrenaline-dopamine reuptake inhibitor
Dosing Guide
Do not exceed 0.5mg daily. Tesofensine has monoamine reuptake inhibition properties similar to antidepressants. Monitor for mood changes and report adverse events.
Standard / Gradual Approach
standardPhaseDose
Week 10.25mg
Week 20.25mg
Week 30.5mg
Week 40.5mg
Protocol Summary
Oral: once daily · Dose range 0.25–1 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
Oral
Recommended frequency: 1x daily, preferably in the morning to avoid potential insomnia. Continuous use, with regular monitoring of weight, metabolic parameters, and potential side effects.
💊 Quick Start
Potential Benefits & Use Cases
Tesofensine is not approved by the FDA and is in clinical development. Use only under medical supervision or approved research protocols.
Inhibits reuptake of dopamine, serotonin, and norepinephrine
Demonstrated weight loss in Phase II obesity trials
Reduces appetite and increases satiety in clinical models
Studied for potential metabolic improvement in obese individuals
No significant cardiovascular side effects in short-term trials
Clinical data Strong preclinical Limited data
Mechanism of Action
→Serotonin reuptake inhibition
→Noradrenaline reuptake inhibition
→Dopamine reuptake inhibition
Lifestyle & Optimization
timing
Take dose in morning to minimize sleep disruption from CNS stimulation.
diet
Consistent meal timing. Monitor caffeine intake — stimulant interactions may occur.
exercise
Exercise 4–5 times weekly.
sleep
Sleep 7–9 hours despite mild stimulant effects.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Dry mouth
• Constipation
• Insomnia
Contraindications & Warnings
• Potential for increased blood pressure
• Not recommended for patients with cardiovascular disease
Long-Term Safety Data
• Effects on long-term safety and mortality not fully established
🧬
Bioavailability & Absorption
SubQ Injection
Not applicable as Tesofensine is administered orally.
Oral Administration
Adequate bioavailability observed with oral administration but benefits from absorption enhancers.
Half-Life
20-22 hours
Degradation
Primarily hepatic metabolism
Tissue Specificity
Affects central nervous system receptors
⚗️
Peptide Details
Molecular Weight
328.28
Formula
C17H23Cl2NO
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
Store capsules at room temperature (15-25°C) away from moisture. Keep in original bottle with desiccant packet. Shelf life is typically 24-36 months.
Reconstituted (Mixed)
Refrigerate at 2–8°C after reconstitution. Use within 28 days.